| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Xuan,Chang-You | Chairman | 15.31% | MERIDIGEN BIOTECH CO., LTD |
| Cai,Jian-Fang | Vice Chairman | 0.32% | MERIDIGEN BIOTECH CO., LTD |
| Xuan,Ming-Zhi | Director | 15.31% | MERIDIGEN BIOTECH CO., LTD |
| Chen,Bai-Tong | Director | 0.08% | |
| Wang,Jia-Xiang | Independent Director | 0.00% | |
| Yang,Bo-Min | Independent Director | 0.00% | |
| Xu,Hui-Yue | Independent Director | 0.00% |
Change Company Name to MERIBANK BIOTECH CO., LTD
2024/06/05
Change Capital to 1,700,000,000
2024/01/10
Change Company Name to XUANJIE STEM CELL BIOTECHNOLOGY CO., LTD. (FORMER NAME: DAZHAN STEM CELL BIOTECHNOLOGY CO., LTD.)
2022/07/04
Change Capital to 1,000,000,000
2021/08/25
Change Person in Charge to Xuan,Chang-You
2018/07/23
Change Capital to 700,000,000
2016/04/28
Change Person in Charge to Xuan,Ming-Zhi
2013/09/17
Change Company Name to MERIBANK BIOTECH CO., LTD
2013/08/09
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 366,430 | 234,342 | 180,120 |
| Operating cost | 172,489 | 95,472 | 85,350 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 193,941 | 138,870 | 94,770 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 193,941 | 138,870 | 94,770 |
| Operating expenses | 281,843 | 262,024 | 204,553 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -87,902 | -123,154 | -109,783 |
| Non-operating income and expenses | -13,646 | -6,792 | 6,556 |
| Net profit (loss) before tax | -101,548 | -129,946 | -103,227 |
| Income tax expense (benefits) | -4,612 | -441 | -81 |
| Net profit (loss) of ongoing business for the current period | -96,936 | -129,505 | -103,146 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -96,936 | -129,505 | -103,146 |
| Other comprehensive profit (loss), net | -2,585 | 674 | -11,828 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -99,521 | -128,831 | -114,974 |
| Net profit (loss) attributable to owners of parent company | -94,711 | -125,346 | -102,134 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | -2,225 | -4,159 | -1,012 |
| Comprehensive profit (loss) attributable to owners of parent company | -97,296 | -124,672 | -113,962 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | -2,225 | -4,159 | -1,012 |
| Basic earnings per share (yuan) | -1 | -1 | -1 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | -38,086 | -29,699 | -41,329 |
| Net cash inflows (outflows) from investing activities | -362,459 | 48,152 | -45,009 |
| Net cash inflow (outflow) from financing activities | 166,173 | 295,846 | -20,655 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | -234,372 | 314,299 | -106,993 |
| Beginning balance of cash and cash equivalents | 399,458 | 85,159 | 192,152 |
| Ending balance of cash and cash equivalents | 165,086 | 399,458 | 85,159 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 393,309 | 570,185 | 392,897 |
| Non-current asset | 2,288,627 | 491,823 | 453,428 |
| Total asset | 2,681,936 | 1,062,008 | 846,325 |
| Current liability | 232,226 | 126,911 | 109,066 |
| Non-current liability | 1,232,328 | 263,901 | 263,466 |
| Total liability | 1,464,554 | 390,812 | 372,532 |
| share capital | 879,764 | 709,764 | 627,764 |
| Equity - secruity token | - | - | - |
| capital reserve | 710,816 | 233,201 | 203,243 |
| retained earning | -373,230 | -272,196 | -350,093 |
| Other equity | -11,622 | -9,037 | -9,711 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 1,205,728 | 661,732 | 471,203 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | 11,654 | 9,464 | 2,590 |
| Total Equity | 1,217,382 | 671,196 | 473,793 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 13 | 9 | 7 |
Others
2021
Compensation for damage
2022
Pay construction fees, etc.
2017, 2018, 2020
Request for damage compensation
2020
Others
2020, 2021, 2022, 2024
Refund
2020
Pay off debt
2021, 2024
Payment order
2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024
Pay service fee
2019, 2020, 2021, 2022, 2023, 2024
Pay remuneration
2020
Pay service fees, etc.
2022
Debt default compensation
2019, 2020, 2022
Pay sale price in installments
2021
